Repligen Stock News

Crossmark Global Holdings Inc. cut its stake in Repligen Co. (NASDAQ:RGEN) by 5.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,080 shares of the biotechnology companys stock after selling 380 shares during the quarter. Crossmark Global Holdings Inc.s holdings in Repligen []

Zacks Investment Research upgraded shares of Repligen (NASDAQ:RGEN) from a hold rating to a strong-buy rating in a report issued on Tuesday, Zacks.com reports. Zacks Investment Research currently has $285.00 price target on the biotechnology companys stock. According to Zacks, Repligen''s third quarter-results beat estimates on both counts. The companys product franchises continue to witness []

Here is how Repligen (RGEN) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.

Here is how Repligen (RGEN) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.

CENTRAL TRUST Co lifted its position in shares of Repligen Co. (NASDAQ:RGEN) by 531.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 101 shares of the biotechnology companys stock after purchasing an additional 85 shares during the quarter. CENTRAL TRUST Cos holdings []

Raymond James Trust N.A. increased its position in shares of Repligen Co. (NASDAQ:RGEN) by 9.7% in the third quarter, HoldingsChannel reports. The firm owned 1,810 shares of the biotechnology companys stock after acquiring an additional 160 shares during the quarter. Raymond James Trust N.A.s holdings in Repligen were worth $523,000 as of its most recent []

AdvisorNet Financial Inc grew its stake in Repligen Co. (NASDAQ:RGEN) by 255.0% in the third quarter, HoldingsChannel reports. The institutional investor owned 710 shares of the biotechnology companys stock after buying an additional 510 shares during the period. AdvisorNet Financial Incs holdings in Repligen were worth $205,000 as of its most recent filing with the []

Atticus Wealth Management LLC purchased a new position in shares of Repligen Co. (NASDAQ:RGEN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 331 shares of the biotechnology companys stock, valued at approximately $96,000. Other institutional investors and hedge funds have []

Travel stocks, oil prices and bond yields dived; Test and biotech leaders rally toward buy points.

Veriti Management LLC decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 20.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 959 shares of the biotechnology companys stock after selling 250 shares during the quarter. Veriti Management LLCs holdings in Repligen []

Repligen Co. (NASDAQ:RGEN) CEO Anthony Hunt sold 17,355 shares of Repligen stock in a transaction dated Thursday, November 18th. The stock was sold at an average price of $276.85, for a total value of $4,804,731.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. []

Related Stocks: RGEN ,

Repligen Co. (NASDAQ:RGEN) CEO Anthony Hunt sold 17,355 shares of Repligen stock in a transaction on Thursday, November 18th. The shares were sold at an average price of $276.85, for a total value of $4,804,731.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. []

Style Box ETF report for RFG

Analysts forecast that Repligen Co. (NASDAQ:RGEN) will report sales of $179.73 million for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Repligens earnings, with estimates ranging from $177.50 million to $181.56 million. Repligen posted sales of $108.65 million during the same quarter last year, which would indicate a positive year []